EMA adopts new policy on handling information on alleged improprieties from external sources

The European Medicines Agency’s management board has adopted a new policy on how EMA handles allegations of improprieties received from external parties, it was announced today.

These improprieties may include allegations of departures from standards of good practices that could have an impact on the evaluation and supervision of medicines.

The goal is to create an environment where individuals from outside the Agency feel confident to raise their concerns on improprieties in their area of work. The policy helps the EMA assess these reports and coordinate any further investigation in a structured way, while protecting the confidentiality of the reporter.